Skip to main content
Home > The Daily Extra > Company News

Chronological Index of BioCentury Extra, The Daily News: Company News

BioCentury Extra, The Daily News Current Issue
  • COMPANY NEWS: Almirall out-licenses RA compound to Aslan

    Almirall S.A. (Madrid:ALM) granted Aslan Pharmaceuticals Pte. Ltd. (Singapore) worldwide rights to develop LAS186323, a dihydroorotate dehydrogenase (DHODH) inhibitor in Phase I testing for rheumatoid arthritis. Aslan …

    Published on 5/21/2012
  • COMPANY NEWS: GE names Siegel CEO of healthymagination

    General Electric Co. (NYSE:GE) hired Sue Siegel as CEO of healthymagination, GE's $6 billion initiative to improve healthcare. Siegel, formerly a general partner at VC firm Mohr Davidow, replaces Mike Barber, who will …

    Published on 5/21/2012
  • COMPANY NEWS: GSK to co-promote Auxilium's Testim

    Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive rights in the U.S. to co-promote testosterone replacement therapy Testim. Auxilium will book all sales of the topical…

    Published on 5/21/2012
  • COMPANY NEWS: Kinex, Xiangxue in cancer deal

    Kinex Pharmaceuticals LLC (Buffalo, N.Y.) granted Xiangxue Pharmaceutical Co. Ltd. (Shenzhen:300147) exclusive rights in China, Taiwan and Singapore to develop and commercialize KX02 for cancer. KX02 is a lipophilic …

    Published on 5/21/2012
  • COMPANY NEWS: Panel finalizes recommendation against PSA screening

    The U.S. Preventative Services Task Force (USPSTF) issued a final recommendation against using prostate-specific antigen (PSA)-based screening for prostate cancer in all age groups. The task force reiterated last year's…

    Published on 5/21/2012
  • COMPANY NEWS: Pharmaxis seeks U.S. approval of Bronchitol

    Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY) submitted an NDA to FDA for Bronchitol mannitol to treat cystic fibrosis (CF). The formulation of mannitol in a dry powder inhaler system has Orphan Drug and Fast Track designation …

    Published on 5/21/2012
  • COMPANY NEWS: FDA approves Plavix generics

    FDA approved generic versions of Plavix clopidogrel late Thursday as the cardiovascular drug from Sanofi (Euronext:SAN; NYSE:SNY) and Bristol-Myers Squibb Co. (NYSE:BMY) lost market exclusivity. The adenosine …

    Published on 5/18/2012
  • COMPANY NEWS: Agilent to acquire Dako for $2.2B

    Agilent Technologies Inc. (NYSE:A) will acquire cancer diagnostic and tools company Dako A/S (Glostrup, Denmark) for $2.2 billion in cash. Agilent said the acquisition will increase its presence in the life sciences and…

    Published on 5/17/2012
  • COMPANY NEWS: Canada approves Prochymal for GvHD

    Health Canada granted conditional approval to Prochymal from Osiris Therapeutics Inc. (NASDAQ:OSIR) to treat acute graft-versus-host disease (GvHD) in children. Osiris is required to conduct a confirmatory trial of the …

    Published on 5/17/2012
  • COMPANY NEWS: Diabetes company Casigen debuts

    Newco Casigen Pharma Ltd. (Hong Kong, China) debuted on Thursday with an exclusive, worldwide license to small molecules for diabetes and other metabolic disorders from the Guangzhou Institute of Biomedicine and Health,…

    Published on 5/17/2012
  • COMPANY NEWS: Human Genome rejects GSK offer, adopts rights plan

    Human Genome Sciences Inc. (NASDAQ:HGSI) said its board unanimously recommended shareholders reject the hostile tender offer from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to acquire the biotech for $13 per share. Human …

    Published on 5/17/2012
  • COMPANY NEWS: OraSure gains after FDA panel backs OTC HIV test

    OraSure Technologies Inc. (NASDAQ:OSUR) gained $1.85 (20%) to $10.95 on Wednesday after FDA's Blood Products Advisory Committee voted 17-0 late Tuesday that data show the OraQuick In-Home HIV test is safe and effective.…

    Published on 5/16/2012
  • COMPANY NEWS: Piramal to acquire healthcare analytics firm

    Piramal Healthcare Ltd. (BSE:500302; NSE:PIRHEALTH) will acquire healthcare information and analytics company Decision Resources Group (Burlington, Mass.) for about $635 million. Decision Resources, which offers …

    Published on 5/16/2012
  • COMPANY NEWS: SEC investigating Dendreon

    Dendreon Corp. (NASDAQ:DNDN) disclosed in a 10Q filing that the SEC is investigating the company. Dendreon said it does not know the specific focus of the investigation, but believes it may be related to statements and …

    Published on 5/16/2012
  • COMPANY NEWS: Merck KGaA details savings targets for biotech cuts

    Merck KGaA (Xetra:MRK) hopes to achieve EUR 300 million ($386.6 million) in net cost savings by 2014 through the previously announced restructuring of its Merck Serono biotech division. The target, announced Tuesday …

    Published on 5/15/2012
  • COMPANY NEWS: NICE reverses prior decision, backs Zytiga

    The U.K.'s NICE issued draft guidance late Tuesday recommending Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ) in combination with prednisone or prednisolone in patients with metastatic, castration-resistant …

    Published on 5/15/2012
  • COMPANY NEWS: Scil, Ono in protein discovery deal

    Scil Proteins GmbH (Halle, Germany) partnered with Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) to discover and develop therapeutics from Scil's Affilin ubiquitin-based protein libraries. Scil will select and …

    Published on 5/15/2012
  • COMPANY NEWS: F-star names Haurum CEO, Dancer COO

    Antibody company F-star Biotechnologische Forschungs und Entwicklungs GmbH (Vienna, Austria) hired John Haurum as CEO. Haurum is the former VP of research at ImClone Systems Inc., which Eli Lilly and Co. (NYSE:LLY) …

    Published on 5/14/2012
  • COMPANY NEWS: FDA concludes Gilenya safety review

    FDA completed its safety review of Gilenya fingolimod and said it could not definitively conclude that the product contributed to recent deaths of patients receiving the multiple sclerosis drug, including a patient who …

    Published on 5/14/2012
  • COMPANY NEWS: Pharmas provide $23.1M for early stage research

    A group of six pharmas will provide L14.4 million ($23.1 million) to fund a research consortium at the University of Dundee for an additional four years. The Division of Signal Transduction Therapy (DSTT) consortium, …

    Published on 5/14/2012
  • COMPANY NEWS: Zambon exercises option for Newron's safinamide

    Zambon Co. S.p.A. (Bresso, Italy) exercised its option from Newron Pharmaceuticals S.p.A. (SIX:NWRN) to license exclusive rights to develop and commercialize Parkinson's disease therapy safinamide worldwide, excluding …

    Published on 5/14/2012
  • COMPANY NEWS: FDA panel votes in favor of Quad for HIV

    FDA's Antiviral Drugs Advisory Committee voted 13-1 that the benefit-risk profile of the fixed-dose Quad regimen from Gilead Sciences Inc. (NASDAQ:GILD) supports approval to treat HIV-1 infection in treatment-naive …

    Published on 5/11/2012
  • COMPANY NEWS: Advisory committee votes in favor of lorcaserin

    FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 18-4, with one abstention, that the benefit-risk profile for lorcaserin from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) supports approval to treat obesity.…

    Published on 5/10/2012
  • COMPANY NEWS: EC approves Pixuvri for lymphoma

    The European Commission granted conditional approval to an MAA from Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) for Pixuvri pixantrone to treat patients with multiply relapsed or refractory aggressive non-Hodgkin's…

    Published on 5/10/2012
  • COMPANY NEWS: NICE backs Botox for chronic migraine

    The U.K.'s NICE issued a final appraisal determination recommending the use of Botox onabotulinumtoxinA from Allergan Inc. (NYSE:AGN) to prevent chronic migraines in patients who have not responded to at least three …

    Published on 5/10/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.